Clinical Presentation

A 47-year-old man presents with a left lower lobe solitary pulmonary nodule (SPN). PET/CT is obtained for initial staging.

Fig. 73.1

Fig. 73.2

Technique

• The patient is instructed to avoid vigorous exercise for 24 hours prior to the scan, fast for at least 4 hours before the study, drink water during the fasting and uptake periods, and void prior to the scan

• A venous serum glucose sample is obtained prior to the injection of ¹⁸F-FDG (reference range is < 120 mg/dl for non-diabetic patients and < 200 mg/dl for diabetic patients), and the patient’s height and weight are recorded

• A 10-20 mCi dose of ¹⁸F-FDG is injected intravenously (in a dimly lit quiet room for brain PET scans), and the patient is asked to rest comfortably in a room that is kept warm

• Most PET scans are now acquired on a hybrid PET/CT scanner, and a low dose spiral CT is acquired for attenuation correction of the PET images and for anatomic localization. Some centers may choose to perform oral and/or intravenous contrast-enhanced diagnostic CT as part of the PET/CT examination

• Sixty minutes following the ¹⁸F-FDG injection, the spiral CT is performed using a weight-based algorithm from the skull base to the upper thighs (for most oncologic indications), or from the vertex to the feet, or centered over the brain depending on the tumor being evaluated

• A 2D or 3D PET acquisition (depending on the manufacturer) is then performed over the same region (s), and all PET images are corrected for attenuation, detector efficiency, scatter, decay, and random coincidences

• Consistency in ¹⁸